Jocasta Neuroscience completed $35 million Series A Round funding
Sector:
Life Science
08/12/2025
Scottsdale, AZ USA
Jocasta Neuroscience
completed $35 million Series A Round funding. Investors include
True Ventures (lead), Moore Strategic Ventures.
"We were gratified by the exceptional investor interest during our raise and are delighted by the composition of the syndicate that includes both seasoned biotech investors as well as funds and individuals who believe our program has an opportunity to improve the lives of those who are stricken with cognitive decline — a testament to the potential of Klotho and the solid scientific foundation from Dr. Dubal's work at the University of California at San Francisco," said Albert Agro, PhD, CEO of Jocasta. SC8 Investments, Glentura and Yagan Family Foundation also participated in this round.
About
Jocasta Neuroscience, Inc. is a pre-clinical stage biotech company focused on developing a proprietary formulation of a-Klotho protein (JN-0413) to manage cognitive decline associated with various forms of neurodegenerative-induced dementia. Jocasta's foundational data demonstrates the critical role of a-Klotho in health and disease. Results ranging from human genetics (effect of KL mutations in humans) to robust cognitive enhancement in healthy rats, rodent disease models and non-human primates strongly support the advancement of JN-0413 into clinical trials in patients with dementia and cognitive decline.
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
